Browse > Article
http://dx.doi.org/10.5478/MSL.2021.12.4.200

Development of a Sensitive Analytical Method of Polynemoraline C Using LC-MS/MS and Its Application to a Pharmacokinetic Study in Mice  

Pang, Minyeong (College of Pharmacy, Dankook University)
Lee, Jaehyeok (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Jeon, Ji-Hyeon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Song, Im-Sook (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Han, Young Taek (College of Pharmacy, Dankook University)
Choi, Min-Koo (College of Pharmacy, Dankook University)
Publication Information
Mass Spectrometry Letters / v.12, no.4, 2021 , pp. 200-205 More about this Journal
Abstract
Polynemoraline C, a pyridocoumarin alkaloid, exhibits anticholinergic, anti-inflammatory, antitumor, and antimicrobial activities. A sensitive analytical method of polynemoraline C in mouse plasma was developed and validated using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Polynemoraline C and 13C-caffeine (internal standard) in mouse plasma were extracted using a liquid-liquid extraction method coupled with ethyl acetate. This extraction method resulted in high and reproducible extraction recovery in the range of 73.49%-77.31% with no interfering peaks around the peak retention time of polynemoraline C and 13C-caffeine. The standard calibration curves for polynemoraline C were linear over the range of 0.5-200 ng/mL with r2 > 0.985. The accuracy, precision, and the stability of the data were within acceptable limits on the FDA guideline. After intravenous and oral administration of polynemoraline C at doses of 5 and 30 mg/kg, respectively, the present method was successfully applied to the pharmacokinetic study of polynemoraline C. Polynemoraline C in mouse plasma showed a multi-exponential elimination pattern with a high volume of distribution values. This compound's absolute oral bioavailability was found to be 17.0%. Polynemoraline C's newly developed LC-MS/MS method can be used for further studies on the efficacy, toxicity, and biopharmaceutics of polynemoraline C, as well as its pharmacokinetic studies.
Keywords
Polynemoraline C; LC-MS/MS analysis; Pharmacokinetics; Bioavailability;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Zimmer, D. Bioanalysis. 2014, 6, 13, DOI: 10.4155/bio.13.298.   DOI
2 Jeon, J. H.; Lee, J.; Park, J. H.; Lee, C. H.; Choi, M. K.; Song, I. S. Pharmaceutics 2021, 13, 1496, DOI: 10.3390/pharmaceutics13091496.   DOI
3 Grover, A.; Benet. L. Z. AAPS J. 2009, 11, 250, DOI:10.1208/s12248-009-9102-7.   DOI
4 Li, H. Y.; Sun, N. J.; Kashiwada, Y.; Sun, L.; Snider, J. V.; Cosentino, L. M.; Lee, K. H. J. Nat. Prod. 1993, 56, 1130, DOI: 10.1021/np50097a017.   DOI
5 Jeon, J. H.; Lee, J.; Choi, M. K.; Song, I. S. Arch. Pharm. Res. 2020, 43, 1335, DOI: 10.1007/s12272-020-01289-0.   DOI
6 Choi, M. K.; Jin, S.; Jeon, J. H.; Kang, W. Y.; Seong, S. J.; Yoon, Y. R.; Han, Y. H.; Song, I. S. J. Ginseng Res. 2020, 44, 229, DOI: 10.1016/j.jgr.2018.10.006.   DOI
7 Schuhmacher, J.; Buhner, K.; Witt-Laido, A. J. Pharm. Sci. 2000, 89, 1008, DOI: 10.1002/1520-6017(200008)89:8<1008::AID-JPS5>3.0.CO;2-B.   DOI
8 He, X. F.; Wang, X. N.; Fan, C. Q.; Gan, L. S.; Yin, S.; Yue, J. M. Helv. Chim. Acta. 2007, 90, 783, DOI:10.1002/hlca.200790080.   DOI
9 Patal, A. A.; Lad, H. B.; Pandya, K. R.; Patel, C. V.; Brahmbhatt, D. I. J. Med. Chem. 2013, 22, 4745, DOI:10.1007/s00044-013-0489-4.   DOI
10 Jiang, E. Y.; Li, B. T. Science Press. 1979, 30, 87.
11 Chen, C. Y.; Chang, F. R.; Shih, Y. C.; Hsieh, T. J.; Chia, Y. C.; Tsen, H. Y.; Chen, H. C.; Chen, S. J.; Hsu, M. C.; Wu, Y. C. J. Nat. Prod. 2000, 63, 1475, DOI: 10.1021/np000176e.   DOI
12 V. V. Chi. Pharmacy Publisher. 2012, 2, 359.
13 Nguyen T. T. O.; To H. T.; Cao T. H.; Le N. T.; Do T. T.; Nguyen T. M. H. Nat. Prod. Commun. 2017, 1, 1025, DOI: 10.1177/1934578X1701200706.   DOI
14 Yao, J. Z.; Liang, H. Q.; Liao, S. X. Acta Pharm. Sin. B. 1994, 29, 845, See http://www.yxxb.com.cn:8081/aps/CN/abstract/abstract10696.shtml.
15 Wright, C. W.; Marshall, S. J.; Russell, P. F.; Anderson, M. M.; Phillipson, J. D.; Kirby, G. C.; Warhurst, D. C.; Schiff Jr, P. L. J. Nat. Prod. 2000, 63, 1638, DOI:10.1021/np000144r.   DOI
16 Kanokmedhakul, S.; Kanokmedhakul, K.; Yodbuddee, D.; Pheonkerd, N. J. Nat. Prod. 2003, 66, 616, DOI:10.1021/np020498d.   DOI
17 Yoon, J. A.; Han, Y. T. Synthesis. 2019, 51, 4611, DOI:10.1055/s-0037-1610730.   DOI
18 Unangst, P. C.; Connor, D. T.; Stabler, S. R.; Weikert, R. J.; Carethers, M. E.; Kennedy, J. A.; Thueson, D. O.; Chestnut, J. C.; Adolphson, R. L.; Conroy, M. C. J. Med. Chem. 1989, 32, 1360, DOI: 10.1021/jm00126a036.   DOI
19 Khan, I. A.; Kulkarni, M. V.; Gopal, M.; Shahabuddin, M.; Sun, C. M. Bioorg. Med. Chem. Lett. 2005, 15, 3584, DOI: 10.1016/j.bmcl.2005.05.063.   DOI
20 Raev, L.; Voinova, E.; Ivanov, I. C.; Popov, D. Pharmazie 1990, 45, 696.
21 Lu, Z. M.; Zhang, Q. J.; Chen, R. Y.; Yu, D. Q. J. Asian Nat. Prod. Res. 2008, 10, 656, DOI: 10.1080/10286020802242281.   DOI